ScreenerHero

PRQR ProQR Therapeutics N.V.

NAS · US · Healthcare · Biotechnology · proqr.com
1.630USD-1.21%Mkt Cap: 230.02M $P/E: —

ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing techn…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap230.02M USD
Enterprise Value131.04M USD
Revenue (TTM)18.42M USD
Gross Profit18.42M USD
Net Income (TTM)-42.18M USD
Revenue/Share0.17 USD
Last Price1.630 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees186
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.49
PEG—
EV/EBITDA-3.13
EV/Revenue7.11
P/S12.64
P/B2.56
EPS (TTM)-0.45
EPS (Forward)-0.47
52W Range
1.33017% of range3.100
52W High3.100 USD
52W Low1.330 USD
Profitability
Gross Margin100.00%
Oper. Margin-100.72%
EBITDA Margin-227.44%
Profit Margin-265.21%
ROE-85.44%
ROA-37.41%
Growth
Revenue Growth120.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF-52.79M USD
CapEx (TTM)1.02M USD
FCF Margin-103.53%
FCF Yield-8.29%
Net Debt-101.81M USD
Net Debt/EBITDA2.43
Balance Sheet
Debt/Equity0.32
Current Ratio3.49
Quick Ratio3.41
Book Value/Sh0.64 USD
Cash/Share0.83 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.1 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)7.778 USD
Upside (mean)+377.2%
Target Range3.000 USD – 10.00 USD
3.000+377.2% to mean10.00
# Analysts9
Ownership
Shares Out.141.12M
Float91.44M
Insiders17.16%
Institutions53.93%
Short Interest
Short Ratio2.6d
Short % Float2.24%
Short % Out.1.70%
Shares Short2.41M
Short (prev mo.)2.22M
Technical
SMA 501.929 (-15.5%)
SMA 2001.747 (-6.7%)
Beta0.20
S&P 52W Chg15.78%
Avg Vol (30d)768.35K
Avg Vol (10d)759.94K
Technical Indicators
RSI (14)34.6
MACD-0.0929
MACD Signal-0.0793
MACD Hist.-0.0136
BB Upper2.080 USD
BB Middle1.779 USD
BB Lower1.477 USD
BB Width33.88%
ATR (14)0.0966 USD
Vol Ratio (20d)0.60x